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Omeprazole was shown to improve the anti-cancer effects of the nucleoside analogue
5-fluorouracil. Here, we combined omeprazole with the antiviral nucleoside analogues
ribavirin and acyclovir. Omeprazole did not affect the antiviral effects of ribavirin in non-
toxic concentrations up to 80 µg/mL but increased the acyclovir-mediated effects
on herpes simplex virus 1 and 2 (HSV-1 and -2) replication in a dose-dependent
manner. Omeprazole alone reduced HSV-1 and -2 titers [but not HSV-induced formation
of cytopathogenic effects (CPE)] at concentrations ≥40 µg/mL. However, it exerted
substantially stronger effects on acyclovir activity and also increased acyclovir activity
at lower concentrations that did not directly interfere with HSV replication. Omeprazole
80 µg/mL caused a 10.8-fold (Vero cells) and 47.7-fold (HaCaT cells) decrease of the
acyclovir concentrations that reduced HSV-1-induced CPE formation by 50% (IC50).
In HSV-2-infected cells, omeprazole 80 µg/mL reduced the acyclovir IC50 by 7.3- (Vero
cells) and 12.9-fold (HaCaT cells). In HaCaT cells, omeprazole 80 µg/mL reduced the
HSV-1 titer in the presence of acyclovir 1 µg/mL by 1.6 × 105-fold and the HSV-2 titer
in the presence of acyclovir 2 µg/mL by 9.2 × 103-fold. The proton pump inhibitors
pantoprazole, rabeprazole, lansoprazole, and dexlansoprazole increased the antiviral
effects of acyclovir in a similar fashion as omeprazole, indicating this to be a drug class
effect. In conclusion, proton pump inhibitors increase the anti-HSV activity of acyclovir
and are candidates for antiviral therapies in combination with acyclovir, in particular for
topical preparations for the treatment of immunocompromised individuals who are more
likely to suffer from severe complications.
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INTRODUCTION
Omeprazole and other proton pump inhibitors have been found to increase the activity
of anti-cancer drugs including the nucleoside analogue 5-fluorouracil (Luciani et al.,
2004; Ikemura et al., 2017). Proton pump inhibitors are the most frequently prescribed
drugs for the treatment and prophylaxis of gastroesophageal reflux as well as of
gastric and duodenal ulcers that are associated with hyper-acidic states. Since they are
known to be well-tolerated, they were suggested as repositioning candidates for the
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use as part of anti-cancer therapies (Luciani et al., 2004;
Ikemura et al., 2017).
Nucleoside analogues are also widely used as antiviral
drugs (Chaudhuri et al., 2018; Chemaly et al., 2019). Here,
we investigated the effects of omeprazole on the efficacy of
the antiviral nucleoside analogues acyclovir and ribavirin. The
guanosine analogue acyclovir and its pro-drug valacyclovir are
used for the treatment of disease caused by herpes simplex
virus 1 (HSV-1) and 2 (HSV-2) and varicella zoster virus
(VZV) (Zarrouk et al., 2017). Acyclovir is activated by the viral
thymidine kinase and then di- and tri-phosphorylated by cellular
kinases. The active tri-phosphorylated forms of acyclovir and
then specifically interferes with the viral DNA polymerase and
causes chain termination (Piret and Boivin, 2016; Chen et al.,
2017; Zarrouk et al., 2017). Ribavirin is a guanosine analogue
that has been shown to exert broad-spectrum activity against
RNA and DNA viruses including influenza viruses and West Nile
virus. The mechanisms by which ribavirin interferes with virus
replication are not clear and may be virus-dependent (Sidwell
et al., 1972; Day et al., 2005; Beaucourt and Vignuzzi, 2014;
Koh and Liang, 2014; Galli et al., 2018; Jordan et al., 2018;
Keppeke et al., 2019). Our findings show that omeprazole (and
other proton pump inhibitors) increase the antiviral activity of
acyclovir but not that of ribavirin.
MATERIALS AND METHODS
Cell Culture
Vero and MDCK cells were obtained from the American
Type Culture Collection (ATCC, Rockville, MD, United States)
and cultured at 37◦C in minimum essential medium (MEM)
supplemented with 10% fetal bovine serum. HaCaT cells were
purchased from CLS Cell Line Services GmbH (Eppelheim,
Germany) and cultivated in Iscove’s modified Dulbecco’s medium
(IMDM) supplemented with 10% fetal bovine serum.
Viruses
HSV-1 strain McIntyre and HSV-2 strain MS were both obtained
from ATCC. West Nile virus (WNV) strain NY385-99 was kindly
provided by Dr. J. ter Meulen (Institut für Virologie, Philipps-
Universität, Marburg, Germany). Virus stocks were prepared in
Vero cells grown in MEM with 4% fetal bovine serum. The
influenza virus strain Influenza A/New Caledonia/20/99 (H1N1)
was received from the WHO Influenza Centre (National Institute
for Medical Research, London, United Kingdom). Virus stocks
were prepared in MDCK cells grown in 4% fetal bovine serum.
Infectious virus titers were determined by titration on MDCK cell
monolayers in 96-well plates and expressed as 50% tissue culture
infectious dose (TCID50) by the method of Spearman and Kärber
(Spearman, 1908; Kärber, 1931).
Drugs
Acyclovir was received from GlaxoSmithKline (Munich,
Germany), omeprazole from AstraZeneca (Wedel, Germany),
ribavirin from Valeant Pharmaceuticals Germany GmbH
(Eschborn, Germany), and pantoprazole, rabeprazole,
lansoprazole, and dexlansoprazole from Selleck Chemicals
(via Absource Diagnostics GmbH, Munich, Germany).
Cytopathogenic Effect (CPE) Reduction
Assay
For the investigation of HSV-1- and HSV-2-induced
cytopathogenic effects (CPEs), confluent Vero or HaCaT
cell monolayer in 96-well microtiter plates were inoculated with
HSV-1 or HSV-2 at MOI 1 or 0.1, respectively. Following a 1 h
incubation period, the inoculum was removed and the drugs,
either alone or in combination, were added. The virus-induced
CPE was recorded microscopically after 48 h post infection.
For the investigation of WNV-induced CPEs, Vero cell
monolayers were infected with MOI 0.1. Following a 1 h virus
incubation period, the medium was removed and replaced by
medium containing different drug concentrations. The CPE was
recorded at 48 h post infection.
Confluent MDCK cell monolayers were infected with
Influenza H1N1 (MOI 0.01). Following a 1 h virus incubation
period, the medium was removed and infected cells were
incubated in medium containing different concentrations of
drugs at the respective concentration. The CPE was recorded at
24 h post infection.
Cytopathogenic effects were scored by two independent
examiners and expressed in% of the untreated virus control that
was defined to be 100%.
Immunostaining
Intracellular HSV protein was evaluated by immunostaining.
Cells were fixed with 60/40 ice cold methanol/acetone for 15 min.
Staining was performed using a rabbit polyclonal antibody
directed against HSV-1 (ab9533) and a sheep polyclonal antibody
directed against HSV-2 (ab21112) in combination with biotin-
conjugated secondary goat anti-rabbit (ab6720) and rabbit anti-
sheep (ab6746) antibodies (all antibodies derived from Abcam,
Cambridge, United Kingdom). Protein was visualized using
streptavidin peroxidase complex with AEC as a substrate.
Viability Assay
The cellular viability was assessed on confluent cell layers with
the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) assay method as described previously (Michaelis
et al., 2007). The viability was expressed as percentage of
non-treated control.
Western Blot
Cells were lysed using Triton-X-100 sample buffer, and proteins
were separated by SDS-PAGE. Detection occurred by using
specific antibodies against HSV-1/2 gB (10B7) (sc-56987, Santa
Cruz Biotechnology, Dallas, TX, United States) and α-tubulin
(ab4074, Abcam, Cambridge, United Kingdom). Proteins were
visualized by enhanced chemiluminescence using a commercially
available kit (Bio-Rad, Feldkirchen, Germany).
Statistics
Results are expressed as mean ± S.D. of at least three
experiments. Comparisons between two groups were performed
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using Student’s t-test. Three and more groups were compared by
ANOVA followed by the Student-Newman–Keuls test. P-values
lower than 0.05 were considered to be significant.
RESULTS
Effects of Omeprazole on Cell Viability
The effects of omeprazole on the viability of the investigated
cell lines was tested in concentrations of up to 160 µg/mL.
Omeprazole concentrations of 80 µg/mL and lower did not
affect the viability of any of the tested cell lines. Omeprazole
160 µg/mL resulted in a reduction of cell viability, but the
concentration that reduces cell viability by 50% (CC50) was not
reached (Supplementary Figure S1).
Effects of Omeprazole in Combination
With Ribavirin on Cytopathogenic Effect
(CPE) Formation in WNV- or Influenza A
H1N1-Infected Cells
Omeprazole 80 µg/mL did not alter the effects of ribavirin on
CPE formation in WNV-infected Vero cells or H1N1-infected
MDCK cells (Figure 1A and Supplementary Table S1).
FIGURE 1 | Cytopathogenic effect (CPE) formation and viral gene expression in the presence of antiviral nucleoside analogues and omeprazole. (A) Effects of
omeprazole (80 µg/mL) on the concentrations of antiviral nucleoside analogues that reduce CPE formation by 50% (IC50) using West Nile virus (WNV)-infected Vero
cells, influenza A H1N1-infected MDCK cells, and HSV-1- or HSV-2-infected Vero or HaCaT cells. Omeprazole alone did not reduce CPE formation. Numerical
values are presented in Supplementary Table S1. (B) Effects of omeprazole and acyclovir on the expression of virus proteins in HSV-1- and HSV-2-infected Vero
cells. HSV-1-infected cells were treated with omeprazole 80 µg/mL and/or acyclovir 0.31 µg/mL. HSV-2-infected cells were treated with omeprazole 40 µg/mL
and/or acyclovir 0.6 µg/mL. (C) HSV gB levels in HSV-1-infected Vero cells treated with omeprazole 80 µg/mL and/or acyclovir 0.31 µg/mL as determined by
Western blot 24 h post infection.
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FIGURE 2 | Concentration-dependent effects of omeprazole on the acyclovir IC50 in HSV-1- or HSV-2-infected HaCaT cells as determined by cytopathogenic effect
(CPE) formation. Numerical values are presented in Supplementary Table S2. The investigated drug concentrations did not affect cell viability, neither alone or in
combination. ∗P < 0.05 relative to nucleoside analogue alone.
Effects of Omeprazole in Combination
With Acyclovir on HSV-1 and HSV-2
Replication
HSV-1- and HSV-2-induced CPE formation were investigated
in Vero and HaCaT cells. Vero is a continuous cell line
derived from kidney epithelial cells of an African green monkey
(Yasumura and Kawakita, 1963). Vero cells are interferon-
deficient and used to cultivate many different viruses (Desmyter
et al., 1968; Montagnon and Vincent-Falquet, 1998; Barrett
et al., 2009). HaCaT is a spontaneously immortalized human
keratinocyte cell line (Boukamp et al., 1988). Omeprazole
on its own did not affect HSV-1- and HSV-2-induced CPE
formation (Supplementary Table S1). In the presence of
omeprazole 80 µg/mL, however, acyclovir concentrations that
reduced CPE formation by 50% (IC50) were reduced by 11-
fold in HSV-1-infected Vero cells and by 7-fold in HSV-2-
infected Vero cells (Figure 1A and Supplementary Table S1).
Further, omeprazole 80 µg/mL reduced the acyclovir IC50s
by 48-fold in HSV-1-infected HaCaT cells and by 13-fold in
HSV-2-infected HaCaT cells (Figure 1A and Supplementary
Table S1). Immune staining also indicated reduced numbers
of virus-infected cells after treatment with a combination of
omeprazole and acyclovir compared to either single treatment
(Figure 1B). In agreement, Western blot analysis demonstrated
strongly reduced HSV gB protein levels in cells treated with
this combination (Figure 1C). Further experiments indicated
that omeprazole reduced acyclovir IC50s in HSV-1- and HSV-2-
infected HaCaT cells in a dose-dependent fashion (Figure 2 and
Supplementary Table S2).
Although omeprazole did not affect the HSV-1 and HSV-2
CPEs in concentrations of up to 80 µg/mL, the determination
of virus titers in Vero cells showed that 80 µg/mL omeprazole
inhibited the production of infectious HSV-1 particles and
that 40 and 80 µg/mL omeprazole inhibited the production
of infectious HSV-2 particles. In agreement with the findings
from the CPE assays, omeprazole also strongly increased
the anti-HSV-1 and anti-HSV-2 effects of acyclovir. Notably,
this omeprazole-induced increase of acyclovir activity was
also seen at lower omeprazole concentrations, which did not
directly reduce virus titers (Figure 3 and Supplementary
Table S3). The investigated omeprazole and acyclovir
concentrations did not affect cell viability, neither alone
not in combination.
Effects of Various Proton Pump
Inhibitors on HSV-1-Induced
Cytopathogenic Effects (CPEs)
Finally, we tested the effects of the additional proton pump
inhibitors pantoprazole, rabeprazole, lansoprazole, and
dexlansoprazole (Li et al., 2017) on CPE formation in HSV-
1-infected HaCaT cells. All tested proton pump inhibitors
increased the activity of acyclovir (Figure 4 and Supplementary
Table S4), which suggests that this is a drug class effect.
DISCUSSION
Based on previous investigations that showed that omeprazole
increases the anti-cancer activity of the nucleoside analog
5-fluorouracil (Luciani et al., 2004), we here investigated the
effects of omeprazole on the antiviral effects of ribavirin
and acyclovir. Omeprazole did not modify ribavirin-mediated
effects in H1N1 influenza A virus-infected or West Nile virus-
infected cell cultures but increased the efficacy of acyclovir, a
first line drug for HSV-1, HSV-2, and varicella zoster virus
infection (Piret and Boivin, 2016; Klysik et al., 2018), in a
dose-dependent fashion in Vero and HaCaT cells. It remains
unclear why omeprazole increases the activity of acyclovir
but not that of ribavirin. Differences between the compounds
acyclovir and ribavirin including their mechanisms of action
and/or differences between the investigated viruses may be
responsible for this.
The mechanism by which omeprazole enhances the activity
of acyclovir seems to differ from the mechanism by which
omeprazole increases 5-fluorouracil efficacy, which was shown
to be the consequence of an increase of the lysosomal pH
(Luciani et al., 2004). Lysosomotropic drugs such as chloroquine
and ammonium chloride are known to interfere with the
infection of viruses including HSV. These drugs increase
intracellular pH presumably resulting in inhibition of viral
packing and maturation through trans-Golgi network, although
their exact mechanisms of antiviral activity remain unclear
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FIGURE 3 | Effect of acyclovir 1 µg/mL (HSV-1) or 2 µg/mL (HSV-2) alone or
in combination with varying omeprazole (OME) concentrations (µg/mL) on
HSV-1 and HSV-2 titres in HaCaT cells. Numerical values are presented in
Supplementary Table S3. ∗P < 0.05 relative to acyclovir alone, #P < 0.05
relative to untreated virus control; N.D. = no detectable virus titre.
FIGURE 4 | Effects of different proton pump inhibitors on acyclovir activity in
HSV-1-infected HaCaT cells as indicated by cytopathogenic effect (CPE)
formation. Proton pump inhibitors alone did not reduce CPE formation.
Numerical values are presented in Supplementary Table S4. ∗P < 0.05
relative to acyclovir alone.
(Koyama and Uchida, 1984, 1989; Johnson and Baines, 2011; Al-
Bari, 2017; Salata et al., 2017). In agreement, omeprazole
concentrations ≥40 µg/mL reduced HSV-1 and HSV-2 titers.
However, the effects of omeprazole on the anti-HSV activity
of acyclovir were more pronounced than the direct antiviral
effects and lower omeprazole concentrations, which did not
affect HSV-1 and HSV-2 replication, still substantially enhanced
the efficacy of acyclovir. This indicates that the induction of
increased acyclovir activity is not a direct consequence of
antiviral activity exerted by omeprazole and may be caused
by a different mechanism. Moreover, omeprazole pre-treatment
was necessary to increase 5-fluorouracil activity (Luciani et al.,
2004), but omeprazole and acyclovir exerted their combined
activity when added at the same time 1 h post infection. This
indicates that the mechanisms by which omeprazole increases
5-fluorouracil and acyclovir activity differ and that omeprazole
increases the antiviral activity of acyclovir during the viral
replication cycle after infection and virus internalization. The
proton pump inhibitors pantoprazole, rabeprazole, lansoprazole,
and dexlansoprazole increased acyclovir activity in a similar
manner as omeprazole. Hence, the capacity to increase the
antiviral activity of acyclovir seems to be a drug class effect,
which is common to proton pump inhibitors in general.
Notably, proton pump inhibitors have been shown to exert
anti-inflammatory and antioxidative effects independently of
their effects on H+/K+ ATPase activity, which may contribute
to the increased acyclovir activity mediated by proton pump
inhibitors (Balza et al., 2016; Nelson et al., 2017; Ghebre, 2018). In
addition, omeprazole may inhibit DNA damage repair (Martelli
et al., 1998), which may increase the efficacy of acyclovir.
Therefore, proton pump inhibitors may increase acyclovir
activity by mechanisms that do not involve the modulation of
the lysosomal pH.
Since omeprazole is a clinically well-established drug with a
preferable safety profile, it is an excellent candidate for drug
repositioning strategies (Ikemura et al., 2017), and there is a
need for improved therapies for HSV-1- and HSV-2-associated
disease. After primary infection, HSV-1 and HSV-2 establish life-
long persistence which may result in recurrent disease which
typically manifests as herpes labialis or herpes genitalis and
which may be associated with significant morbidity (Gnann
and Whitley, 2016; Heslop et al., 2016; Klysik et al., 2018).
Even in the case of herpes labialis, which is not commonly
associated with severe complications, treatment success is not
always satisfactory as highlighted by the introduction of topical
acyclovir/hydrocortisone combinations (Nguyen et al., 2014).
Omeprazole may not exert general immunosuppressive effects
in the same way as hydrocortisone but to more specifically
increase acyclovir activity. In immunodeficiency individuals,
HSV-1 and -2 infections are often associated with more severe
disease, and resistance formation to acyclovir is a severe problem
(Piret and Boivin, 2016; Karrasch et al., 2018). Moreover, ocular
HSV infection is a major cause of blindness in industrialized
countries (Klysik et al., 2018). Thus, more effective treatment
options for HSV-1- and HSV-2-caused disease are highly
desirable. In this context, proton pump inhibitors are promising
candidates for combination with acyclovir or valacyclovir in
topical preparations. Further research will have to show to
which extent effective proton pump inhibitor concentrations
can also be achieved systemically. For omeprazole, maximum
plasma levels have been described to reach about 8 µg/mL,
when it is used for inhibition of acid secretion in the
stomach (Shin and Kim, 2013). Hence, the achievement of
therapeutically effective plasma concentrations seems possible,
given that a dose increase may be feasible in a severe acute
disease setting.
In conclusion, omeprazole and other proton pump inhibitors
substantially enhance the antiviral effects of acyclovir in HSV-
1- and HSV-2-infected cells. With their known safety profiles,
proton pump inhibitors are promising candidates for drug
repurposing approaches (Ikemura et al., 2017), in particular for
topical preparations.
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